ArticleOncotarget2015
MicroRNA-155 expression is independently predictive of outcome in chordoma.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis.Molecular diagnosis & therapy · 2023Pooled it
- Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets.Current drug targets · 2024Review
- Simultaneous Targeting of Multiple oncomiRs with Phosphorothioate or PNA-Based Anti-miRs in Lymphoma Cell Lines.Pharmaceutical research · 2022Article
- MiR-17 and miR-93 Promote Tumor Progression by Targeting p21 in Patients with Chordoma.OncoTargets and therapy · 2021Article
- Article
- miR-100-5p Inhibits Malignant Behavior of Chordoma Cells by Targeting IGF1R.Cancer management and research · 2020Article
- Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma.Frontiers in oncology · 2020Article
- miR-152 inhibits the proliferation and invasion of chordoma cells by targetingThe Journal of international medical research · 2019Article
- The clinical outcomes for chordomas in the cranial base and spine: A single center experience.Medicine · 2019Article
- Upregulation Of miR-149-3p Suppresses Spinal Chordoma Malignancy By Targeting Smad3.OncoTargets and therapy · 2019Article
- Review
- miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3.Cell death & disease · 2018Article
- A giant lumbar chordoma: A case report.Medicine · 2018Article
- MicroRNA-155: a Novel Armamentarium Against Inflammatory Diseases.Inflammation · 2017Review
- Overexpression of miR-31-5p inhibits human chordoma cells proliferation and invasion by targeting the oncogene c-Met through suppression of AKT/PI3K signaling pathway.International journal of clinical and experimental pathology · 2017Article
- The role of microRNAs in gallbladder cancer.Molecular and clinical oncology · 2016Article
- miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2.Oncotarget · 2016Article
- Chordoma: The Quest for Better Treatment Options.Oncology and therapy · 2016Review
- Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.American journal of translational research · 2016Article
- Chordoma: an update on the pathophysiology and molecular mechanisms.Current reviews in musculoskeletal medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundChordoma pathogenesis remains poorly understood. In this study, we aimed to evaluate the relationships between microRNA-155 (miR-155) expression and the clinicopathological features of chordoma patients, and to evaluate the functional role of miR-155 in chordoma.
methodsThe miRNA expression profiles were analyzed using miRNA microarray assays. Regulatory activity of miR-155 was assessed using bioinformatic tools. miR-155 expression levels were validated by reverse transcription-polymerase chain reaction. The relationships between miR-155 expression and the clinicopathological features of chordoma patients were analyzed. Proliferative, migratory and invasive activities were assessed by MTT, wound healing, and Matrigel invasion assays, respectively.
resultsThe miRNA microarray assay revealed miR-155 to be highly expressed and biologically active in chordoma. miR-155 expression in chordoma tissues was significantly elevated, and this expression correlated significantly with disease stage (p = 0.036) and the presence of metastasis (p = 0.035). miR-155 expression also correlated significantly with poor outcomes for chordoma patients (hazard ratio, 5.32; p = 0.045). Inhibition of miR-155 expression suppressed proliferation, and the migratory and invasive activities of chordoma cells.
conclusionsWe have shown miR-155 expression to independently affect prognosis in chordoma. These results collectively indicate that miR-155 expression may serve not only as a prognostic marker, but also as a potential therapeutic target in chordoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.